Details for Patent: 11,091,759

Which drugs does patent 11,091,759 protect, and when does it expire?

Patent 11,091,759 protects QFITLIA and is included in one NDA.

This patent has forty-four patent family members in twenty-four countries.

Summary for Patent: 11,091,759

Title:	Methods and compositions for treating a Serpinc1-associated disorder
Abstract:	The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.
Inventor(s):	Akin Akinc, Benny Sorensen, Pushkal Garg, Gabriel Robbie
Assignee:	Genzyme Corp
Application Number:	US15/371,300
Patent Claim Types: see list of patent claims	Use; Formulation;

error: insufficient information

Drugs Protected by US Patent 11,091,759

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-001	Mar 28, 2025		RX	Yes	Yes						ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA A OR B WITH OR WITHOUT FACTOR VIII OR IX INHIBITORS
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-002	Mar 28, 2025		RX	Yes	Yes						ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA A OR B WITH OR WITHOUT FACTOR VIII OR IX INHIBITORS

International Family Members for US Patent 11,091,759

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016368289
Australia	2023200828
Australia	2025201684
Brazil	112018011450
Canada	3007014
China	108601795